BioGaia ABBGLAF 100 EV-to-FCF is 31.82 as of Jun. 28, 2026, which is 5% below its 10-year median of 33.41. GuruFocus rates BGLAF with a GF Score™ of 100/100 and a GF Value™ of $13.05. The stock has 5 warning signs investors should review. Among 562 Drug Manufacturers companies, BioGaia AB ranks worse than 62.81% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, BioGaia AB's Enterprise Value is $1,143.4 Mil.
BioGaia AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $35.9 Mil. Therefore, BioGaia AB's EV-to-FCF for today is 31.82.
The historical rank and industry rank for BioGaia AB's EV-to-FCF or its related term are showing as below:
BGLAF'
s EV-to-FCF Range Over the Past 10 Years
Min: 22.94 Med: 33.41 Max: 81.09
Current: 33.07
During the past 13 years, the highest EV-to-FCF of BioGaia AB was 81.09. The lowest was 22.94. And the median was 33.41.
BGLAF's EV-to-FCF is ranked worse than 62.81% of 562
companies
in the Drug Manufacturers industry
Industry Median: 20.11
vs BGLAF: 33.07
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
BioGaia AB's share price for today is $12.20.
BioGaia AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.349.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
BioGaia AB EV-to-FCF Related Terms
BioGaia AB EV-to-FCF Historical Data
* Premium members only.
The historical data trend for BioGaia AB's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, BioGaia AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioGaia AB EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BioGaia AB's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where BioGaia AB's EV-to-FCF falls into.
BioGaia AB's current Enterprise Value is $1,143.4 Mil.
BioGaia AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $35.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioGaia AB (BGLAF) has a EV-to-FCF of 31.82 as of Jun. 28, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on BioGaia AB and its competitors. This is near median its historical median of 33.41. Over the past decade, BioGaia AB's EV-to-FCF has ranged from 22.94 to 81.09. According to the industry distribution chart, BioGaia AB ranks #353 out of 562 companies in the Drug Manufacturers industry, placing it in the top 62.8%.
Is BioGaia AB's EV-to-FCF too high?
BioGaia AB's current EV-to-FCF of 31.82 is near median its 10-year median of 33.41. Over the past 10 years, this metric has ranged from a low of 22.94 to a high of 81.09. The Drug Manufacturers industry median EV-to-FCF is 20.11. BioGaia AB's value of 31.82 is 58.2% above this industry median. Based on the distribution chart, BioGaia AB ranks #353 out of 562 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, BioGaia AB has a GF Score™ of 100/100, reflecting its overall financial health beyond just this single metric.
How does BioGaia AB's EV-to-FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, BioGaia AB ranks #353 out of 562 companies for EV-to-FCF. This places BioGaia AB in the lower half of its industry. The industry median EV-to-FCF is 20.11. BioGaia AB's value of 31.82 is 58.2% above this benchmark. Historically, BioGaia AB's own EV-to-FCF has ranged from 22.94 to 81.09 over the past decade. While the company's 10-year median is 33.41 vs. the industry median of 20.11, BioGaia AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.11, based on 562 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioGaia AB's current EV-to-FCF of 31.82 is 58.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on BioGaia AB and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioGaia AB's current EV-to-FCF is 31.82, which is near median its own 10-year median of 33.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGaia AB stock overvalued right now?
BioGaia AB (BGLAF) has a current EV-to-FCF of 31.82. The stock's GF Value™ is $13.05, compared to a current price of $12.20 — trading 6.5% below its estimated fair value. The current EV-to-FCF is 31.82, which is near median its 10-year median of 33.41 and 58.2% above the Drug Manufacturers industry median of 20.11. BioGaia AB's overall GF Score™ is 100/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For BioGaia AB (BGLAF), the current EV-to-FCF is 31.82 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioGaia AB (BGLAF) Overvalued in 2026?
Based on GuruFocus' analysis, BioGaia AB stock appears to be undervalued.
The current stock price of $12.20 is trading 6.5% below its estimated GF Value™ of $13.05.
Key valuation signals for BGLAF:
EV-to-FCF: 31.82 (near median its 10-year median of 33.41)
GF Value™: $13.05 vs. price of $12.20 (6.5% below fair value)
Industry Position: 58.2% above the Drug Manufacturers median (#353 of 562)
No single metric tells the full story. See the BGLAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions: EMEA, the Americas, and APAC (Asia-Pacific, Australia, and New Zealand).
100GF Score
Get the complete analysis for BGLAF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BGLAF has been successfully added to your 
